Citi Pharma partners with Mersi Farma to boost API manufacturing

MG News | December 03, 2024 at 02:02 PM GMT+05:00
December 03, 2024 (MLN): Citi Pharma Limited (PSX: CPHL) has forged a strategic partnership with Mersi Farma, an Indonesia-based Based Leading Pharmaceutical Company, to Advance Active Pharmaceutical Ingredient (API) Manufacturing and Expand the Nutraceutical Market in Indonesia.
The company has signed a Memorandum of Understanding (MoU) with Mersi Farma, marking a transformative collaboration to establish API manufacturing facilities and expand nutraceutical product accessibility in Indonesia.
Key Provisions of the Partnership:
1. Development of Advanced API Manufacturing Facilities
- Paracetamol API Plant: A state-of-the-art facility with an annual production capacity of 10,000 metric tons per annum.
- Amoxicillin API Plant: A high-capacity plant with an annual production capacity of 1,800 metric tons per annum. These facilities will meet Pharmaceutical Inspection Co-operation Scheme (PICTS) compliance standards, ensuring the highest quality production processes.
The Paracetamol and Amoxicillin plants will be the first large-scale API manufacturing facilities in Indonesia, significantly reducing the country's dependence on imported APIs.
This strategic initiative aims to bolster local production capacity, enhance self-reliance and contribute to Indonesia's healthcare infrastructure.
2. Joint Investment and Expertise Deployment
- Citi Pharma Limited will provide substantial capital investment and integrate state-of-the-art technology to establish world-class production capabilities.
- Mersi Farma will co-invest and utilize its extensive operational network within Indonesia to oversee operations and optimize market distribution for APIs.
3. Nutraceutical Market Penetration in Indonesia
- Citi Pharma Limited will introduce its premium nutraceutical product range, catering to the growing demand for health and wellness solutions.
- Mersi Farma will manage the marketing, sales and distribution of these products through its robust and well-established local distribution framework.
4. Strategic Implications
This partnership is a cornerstone of shared efforts to:
- Drive innovation in the pharmaceutical and nutraceutical sectors.
- Enhance regional healthcare accessibility through localized and high-quality API manufacturing.
- Promote economic sustainability by reducing Indonesia's reliance on API imports and fostering local industrial growth.
With the first bulk API manufacturing plant in Indonesia, this collaboration represents a pivotal shift toward self-sufficiency and technological advancement in the country's healthcare landscape.
Looking Ahead
Citi Pharma Limited and Mersi Farina are dedicated to making this partnership a model of excellence in pharmaceutical production and distribution.
Copyright Mettis Link News
Related News
Name | Price/Vol | %Chg/NChg |
---|---|---|
KSE100 | 157,953.47 555.47M | 1.14% 1775.65 |
ALLSHR | 96,741.22 1,957.60M | 1.16% 1110.83 |
KSE30 | 48,198.94 249.79M | 1.09% 520.47 |
KMI30 | 232,694.17 290.89M | 1.31% 3011.94 |
KMIALLSHR | 65,027.13 1,019.78M | 1.03% 660.37 |
BKTi | 42,489.56 84.10M | 1.35% 566.75 |
OGTi | 31,779.36 15.21M | 0.14% 43.57 |
Symbol | Bid/Ask | High/Low |
---|
Name | Last | High/Low | Chg/%Chg |
---|---|---|---|
BITCOIN FUTURES | 118,050.00 | 118,295.00 116,115.00 | 2225.00 1.92% |
BRENT CRUDE | 68.18 | 68.42 67.34 | 0.23 0.34% |
RICHARDS BAY COAL MONTHLY | 84.00 | 0.00 0.00 | -0.40 -0.47% |
ROTTERDAM COAL MONTHLY | 94.00 | 94.50 94.00 | 0.45 0.48% |
USD RBD PALM OLEIN | 1,106.50 | 1,106.50 1,106.50 | 0.00 0.00% |
CRUDE OIL - WTI | 63.93 | 64.20 63.11 | 0.23 0.36% |
SUGAR #11 WORLD | 15.98 | 16.27 15.92 | -0.29 -1.78% |
Chart of the Day
Latest News
Top 5 things to watch in this week
Pakistan Stock Movers
Name | Last | Chg/%Chg |
---|
Name | Last | Chg/%Chg |
---|